Cargando…
Modulation of Myogenic Differentiation in a Human Rhabdomyosarcoma Cell Line by a New Derivative of 5‐Fluorouracil (QF‐3602)
The in vitro study of mechanisms involved in drug‐induced maturation has made it possible to use differentiation‐based therapy in clinical practice. The goal of this new therapy is the development of specific agents to induce cancer cells to stop proliferating and express characteristics of normal c...
Autores principales: | Marchal, Juan Antonio, Melguizo, Consolación, Prados, Jose, Aránega, Amelia Eva, Gómez, Jose Antonio, Campos, Joaquin, Gallo, Miguel Angel, Espinosa, Antonio, Arena, Nicolo, Aránega, Antonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926449/ https://www.ncbi.nlm.nih.gov/pubmed/11011122 http://dx.doi.org/10.1111/j.1349-7006.2000.tb01037.x |
Ejemplares similares
-
Multidrug Resistance Phenotype in the RMS‐GR Human Rhabdomyosarcoma Cell Line Obtained after Polychemotherapy
por: Prados, Jose, et al.
Publicado: (1999) -
GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells
por: Marchal, J A, et al.
Publicado: (1999) -
Characterization of a New Human Embryonal Rhabdomyosarcoma Cell Line, RMS‐GR
por: Fernández, Juan Emilio, et al.
Publicado: (1998) -
5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer
por: Ortiz, Raúl, et al.
Publicado: (2012) -
Nanomedicine: Application Areas and Development Prospects
por: Boulaiz, Houria, et al.
Publicado: (2011)